Jim Cramer gave top insight on ImmunityBio, Inc. (NYSE:IBRX), sharing a game plan of what to buy, sell, and hold right now. When a caller mentioned that they have a small position in the stock, Cramer commented:

Okay, that is a pure spec…. I would encourage you to own it, provided you don’t own any other spec, because that company is losing a lot of money.

Photo by Adam Nowakowski on Unsplash

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to strengthen the immune system against infectious diseases and several cancers. A caller asked about the stock during the March 19 episode’s lightning round, and Cramer replied:

ImmunityBio had a big cross of a huge amount of stock, but at the end, I don’t know where that stock went to. I’d like to see the stock come in and see if that block holds before I buy that, because that stock is part of the magical thinking era.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.